Literature DB >> 8737124

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones.

Y Mizuki1, I Fujiwara, T Yamaguchi.   

Abstract

Fluoroquinolone derivatives interact with methylxanthines (theophylline, caffeine) and metallic ion-containing drugs to different degrees. The rat appears to be a suitable model for predicting such interactions in man. It has been possible to determine the relationship between the chemical structure of the fluoroquinolone and the magnitude of the interaction. Fluoroquinolones with a bulky substituent at the position 8, such as sparfloxacin, lomefloxacin and fieroxacin, are less prone to interact with theophylline than those without an 8-substituent, such as enoxacin. This substituent determines the planarity of the whole fluoroquinolone molecule and the interaction tends to be more significant for planar fluoroquinolones. Furthermore, a 4'-nitrogen atom in the 7-piperazinyl group is essential for the interaction to occur. The nitrogen atom is possibly the site that binds cytochrome P-450, which catalyses theophylline metabolism. The reduction in bioavailability of fluoroquinolones by concurrent administration of aluminium hydroxide is more striking for derivatives with fewer substituents on the essential structure and on the piperazinyl group, such as norfloxacin, ciprofloxacin and enoxacin. Substitution at the 5-position diminishes the interaction, which suggests that the 5-substituent may affect the formation and/or stability of unabsorbable chelate complex which is the probable cause of the interaction. These findings are potentially useful in designing fluoroquinolones less prone to drug interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737124     DOI: 10.1093/jac/37.suppl_a.41

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

1.  Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Interactions between new quinolone antibacterials and diagnostic drug containing manganese.

Authors:  Moeko Hosono; Haruko Yokoyama; Risa Takayanagi; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-27       Impact factor: 2.441

4.  Poly[bis-[μ-1-cyclo-propyl-6-fluoro-4-oxido-7-(1-piperazin-yl)-1,4-dihydro-quinoline-3-carboxyl-ato]nickel(II)].

Authors:  Zhe An; Lan-Ru Liu; Ya-Qin Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2007-12-12

5.  catena-Poly[[[(1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxyl-ato-κO,O)copper(II)]-μ-1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxyl-ato-κN:O,O] tetra-hydrate].

Authors:  Shu-Ye Wang; Xue-Ming Song; Li-Xiang Duan; Zhe An
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-23

6.  1-Ethyl-6-fluoro-7-(4-methyl-piperazin-4-ium-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate hexa-hydrate.

Authors:  Zhe An; Qing-Cheng Liang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-01-16

7.  Poly[[bis-[μ(2)-8-ethyl-5-oxo-2-(piperazin-1-yl)-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxyl-ato]manganese(II)] dihydrate].

Authors:  Jing Huang; Wei-Ping Hu; Zhe An
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-03-14

8.  4-(3-Carb-oxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-7-quinol-yl)-1-methyl-piper-azin-ium picrate.

Authors:  Hoong-Kun Fun; Madhukar Hemamalini; Divya N Shetty; B Narayana; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-02-27

9.  Aqua-bis[1-ethyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxyl-ato]zinc(II) dihydrate.

Authors:  Wei Qi; Jing Huang; Zhe An
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-01-09

10.  Poly[[bis-[μ(2)-8-ethyl-5-oxo-2-(piperazin-1-yl)-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxyl-ato]cobalt(II)] dihydrate].

Authors:  Xu Qi; Ming Shao; Chen-Xin Li
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.